About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiology
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
2020 ASCO Virtual Direct™ Highlights
Boston
Breast
GYN
Lung
GI
GU
Skin
Hematologic Oncology
Head&Neck
Supportive/Palliative Care
St. Louis
Breast
GYN
Lung
GI
GU
Skin
Hematologic Oncology
Head&Neck
Supportive/Palliative Care
Basic Science
Jacksonville
Breast
Hematologic Oncology
Lung
GI
GU
GYN
Skin
Head&Neck
Basic Science
Philadelphia
GI
GU
Lung
Skin
Hematologic Oncology
Breast
Supportive/Palliative Care
Head&Neck
GYN
Denver
Breast
Hematologic Oncology
Lung
GU
Skin
GYN
Head&Neck
Basic Science
San Francisco
Breast
Lung
GU
Hematologic Oncology
Skin
GI
GYN
Head&Neck
Business
Las Vegas
GI
GU
Hematologic Oncology
Skin
Lung
Head&Neck
GYN
Business
San Juan
Breast
GI
Hematologic Oncology
Skin
GYN
Basic Science
Head and Neck
Supportive and Palliative Care
Business
Events
GI
08:05
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Highlights on HER2+ mCRC: Is Promising Trastuzumab Deruxtecan Active in Disease Refractory to Standard Therapies?
FEATURING
Shikha Jain
137 views
July 16, 2020
1
06:45
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Highlights on BRAF V600E Mutant mCRC: Does FDA Approved Encorafenib + Cetuximab Significantly Improve OS, ORR, PFS relative vs. SOC?
FEATURING
Shikha Jain
380 views
July 14, 2020
1
08:01
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Highlights on Stage III CRC: Is There a Difference in 5 yr OS Between 3 vs. 6 Months of Adjuvant Therapy?
FEATURING
Shikha Jain
1,204 views
July 14, 2020
4
06:48
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Highlights on CRC: Can We Consider Pembrolizumab a New First Line SoC in Patients With MSI-H mCRC?
FEATURING
Shikha Jain
559 views
July 14, 2020
5
19:45
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Pancreatic Cancer Highlights: Is Perioperative mFOLFIRINOX More Beneficial Than Gem/nab-P in Resectable Disease? Should Neoadjuvant Therapy Be Considered for Borderline Resectable Disease?
FEATURING
Heloisa Soares
828 views
July 14, 2020
5
11:51
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Highlights on Esophageal / Gastric Cancers: Did Trastuzumab + Trimodality Treatment Increase DFS, PCR or OS of Esophageal Cancer? Is Pertuzumab / Trastuzumab + FLOT Showing Promising pCR?
FEATURING
Heloisa Soares
449 views
July 14, 2020
3
05:29
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Highlights on HCC: Donafenib vs. Sorafenib - Which Combination Is Beneficial as First-line Therapy in Advanced Disease?
FEATURING
Heloisa Soares
46 views
July 14, 2020